tracleer bosentan 125mg (as monohydrate) tablet bottle
janssen-cilag pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: magnesium stearate; ethylcellulose; purified talc; pregelatinised maize starch; iron oxide red; iron oxide yellow; glyceryl behenate; triacetin; maize starch; titanium dioxide; sodium starch glycollate; hypromellose; povidone - tracleer is indicated for the treatment of: idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.
bosentan cipla bosentan 125 mg (as monohydrate) tablet blister pack
cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.
bosentan cipla bosentan 125 mg (as monohydrate) tablet bottle
cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.
augmentin 156 susp. 125 mg/5ml, 31.25 mg/5ml
مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - amoxicillin 125 mg/5ml, clavulanic acid 31.25 mg/5ml - 125 mg/5ml, 31.25 mg/5ml
emend
merck sharp & dohme (new zealand) limited - aprepitant 125mg - capsule - 125 mg - active: aprepitant 125mg excipient: gelatin hyprolose microcrystalline cellulose sodium laurilsulfate sucrose - emend, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: · moderately emetogenic cancer chemotherapy. · highly emetogenic cancer chemotherapy.
bosentan viatris
viatris limited - bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg; ; bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg - film coated tablet - 125 mg - active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg excipient: glyceryl behenate magnesium stearate maize starch opadry yellow 03k82318 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg excipient: glyceryl behenate magnesium stearate maize starch opadry white 03k580000 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid - indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.
tracleer
janssen-cilag (new zealand) ltd - bosentan 125mg; - film coated tablet - 125 mg - active: bosentan 125mg excipient: ethylcellulose glyceryl behenate hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch povidone purified talc sodium starch glycolate starch titanium dioxide triacetin - tracleer® is indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.
tracleer tablet 125 mg
johnson & johnson international (singapore) pte ltd - bosentan monohydrate 129.082mg eqv bosentan - tablet, film coated - 125 mg - bosentan monohydrate 129.082mg eqv bosentan 125 mg
dilantin 125® (phenytoin oral suspension usp) 125mg5ml
viatris private limited - phenytoin - suspension - 125.00mg/5ml - phenytoin 125.00mg/5ml
ataxxa 1250 mg/250 mg spot-on solution for dogs over 10 kg up to 25 kg
krka, d.d., novo mesto - permethrin; imidacloprid - spot-on solution - 1250, 250 mg/pipette - permethrin, combinations - dogs - ectoparasiticide